310 related articles for article (PubMed ID: 35611213)
41. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
42. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
43. Ex Vivo and in Vivo Evaluation of the Effect of Coating a Coumarin-6-Labeled Nanostructured Lipid Carrier with Chitosan-N-acetylcysteine on Rabbit Ocular Distribution.
Liu D; Li J; Cheng B; Wu Q; Pan H
Mol Pharm; 2017 Aug; 14(8):2639-2648. PubMed ID: 28664726
[TBL] [Abstract][Full Text] [Related]
44. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
45. In Situ Gel of Triamcinolone Acetonide-Loaded Solid Lipid Nanoparticles for Improved Topical Ocular Delivery: Tear Kinetics and Ocular Disposition Studies.
Tatke A; Dudhipala N; Janga KY; Balguri SP; Avula B; Jablonski MM; Majumdar S
Nanomaterials (Basel); 2018 Dec; 9(1):. PubMed ID: 30591688
[TBL] [Abstract][Full Text] [Related]
46. Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate.
Abdel-Salam FS; Mahmoud AA; Ammar HO; Elkheshen SA
J Liposome Res; 2017 Mar; 27(1):41-55. PubMed ID: 26956098
[TBL] [Abstract][Full Text] [Related]
47. Topical anesthetic analgesic therapy using the combination of ropivacaine and dexmedetomidine: hyaluronic acid modified long-acting nanostructured lipid carriers containing a skin penetration enhancer.
Yang Y; Qiu D; Liu Y; Chao L
Drug Des Devel Ther; 2019; 13():3307-3319. PubMed ID: 31571832
[TBL] [Abstract][Full Text] [Related]
48. Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers.
Raval S; Jani P; Patil P; Thakkar P; Sawant K
Ther Deliv; 2021 Aug; 12(8):583-596. PubMed ID: 34286598
[No Abstract] [Full Text] [Related]
49. Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery.
Shrivastava N; Khan S; Baboota S; Ali J
Curr Drug Deliv; 2018; 15(6):829-839. PubMed ID: 29189155
[TBL] [Abstract][Full Text] [Related]
50. Impact of nanostructured lipid carriers on dapsone delivery to the skin: in vitro and in vivo studies.
Elmowafy M; Shalaby K; Ali HM; Alruwaili NK; Salama A; Ibrahim MF; Akl MA; Ahmed TA
Int J Pharm; 2019 Dec; 572():118781. PubMed ID: 31715347
[TBL] [Abstract][Full Text] [Related]
51. Systematic development and characterization of curcumin-loaded nanogel for topical application.
Kesharwani P; Jain A; Srivastava AK; Keshari MK
Drug Dev Ind Pharm; 2020 Sep; 46(9):1443-1457. PubMed ID: 32644836
[TBL] [Abstract][Full Text] [Related]
52. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy.
Jiang H; Pei L; Liu N; Li J; Li Z; Zhang S
Drug Deliv; 2016 May; 23(4):1379-82. PubMed ID: 26162024
[TBL] [Abstract][Full Text] [Related]
53. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
54. Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers:
Polat HK; Kurt N; Aytekin E; Akdağ Çaylı Y; Bozdağ Pehlivan S; Çalış S
J Ocul Pharmacol Ther; 2022; 38(6):412-423. PubMed ID: 35675672
[No Abstract] [Full Text] [Related]
55. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.
Sathe P; Saka R; Kommineni N; Raza K; Khan W
Drug Dev Ind Pharm; 2019 May; 45(5):826-838. PubMed ID: 30764674
[TBL] [Abstract][Full Text] [Related]
56. Penetration of Nile red-loaded nanostructured lipid carriers (NLCs) across the porcine cornea.
Niamprem P; Srinivas SP; Tiyaboonchai W
Colloids Surf B Biointerfaces; 2019 Apr; 176():371-378. PubMed ID: 30658285
[TBL] [Abstract][Full Text] [Related]
57. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
58. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations.
Mahmood A; Rapalli VK; Gorantla S; Waghule T; Singhvi G
Drug Deliv Transl Res; 2022 May; 12(5):1118-1135. PubMed ID: 33895936
[TBL] [Abstract][Full Text] [Related]
59. Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia evaluation.
Yue Y; Zhao D; Yin Q
Biomed Pharmacother; 2018 Feb; 98():813-820. PubMed ID: 29571251
[TBL] [Abstract][Full Text] [Related]
60. Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation.
Mainuddin ; Kumar A; Ratnesh RK; Singh J; Dumoga S; Sharma N; Jindal A
Med Oncol; 2024 Mar; 41(5):95. PubMed ID: 38526657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
